var data={"title":"Rapid cycling bipolar disorder in adults: Treatment of major depression","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Rapid cycling bipolar disorder in adults: Treatment of major depression</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/rapid-cycling-bipolar-disorder-in-adults-treatment-of-major-depression/contributors\" class=\"contributor contributor_credentials\">Ralph Kupka, MD, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/rapid-cycling-bipolar-disorder-in-adults-treatment-of-major-depression/contributors\" class=\"contributor contributor_credentials\">Paul Keck, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/rapid-cycling-bipolar-disorder-in-adults-treatment-of-major-depression/contributors\" class=\"contributor contributor_credentials\">David Solomon, MD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/rapid-cycling-bipolar-disorder-in-adults-treatment-of-major-depression/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Feb 20, 2018.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H92693288\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Bipolar disorder is characterized by mood episodes that are nearly always recurrent [<a href=\"https://www.uptodate.com/contents/rapid-cycling-bipolar-disorder-in-adults-treatment-of-major-depression/abstract/1,2\" class=\"abstract_t\">1,2</a>]. Patients who experience at least four episodes during a 12-month period are classified as &ldquo;rapid cycling&rdquo; [<a href=\"https://www.uptodate.com/contents/rapid-cycling-bipolar-disorder-in-adults-treatment-of-major-depression/abstract/2\" class=\"abstract_t\">2</a>]. The term was first used in 1974 to describe bipolar patients who were unresponsive to <a href=\"topic.htm?path=lithium-drug-information\" class=\"drug drug_general\">lithium</a> [<a href=\"https://www.uptodate.com/contents/rapid-cycling-bipolar-disorder-in-adults-treatment-of-major-depression/abstract/3\" class=\"abstract_t\">3</a>]. However, it is now clear that pharmacotherapy is often less beneficial for rapid cycling patients than non-rapid cycling patients, and that lithium may be as effective as other drugs for rapid cycling [<a href=\"https://www.uptodate.com/contents/rapid-cycling-bipolar-disorder-in-adults-treatment-of-major-depression/abstract/4\" class=\"abstract_t\">4</a>]. </p><p>This topic reviews the treatment of major depression in rapid cycling patients. The treatment of mania and hypomania in rapid cycling patients, and the epidemiology, pathogenesis, clinical features, and diagnosis of rapid cycling in patients with bipolar disorder are discussed separately, as is the diagnosis and general treatment of bipolar disorder:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=rapid-cycling-bipolar-disorder-in-adults-treatment-of-mania-and-hypomania\" class=\"medical medical_review\">&quot;Rapid cycling bipolar disorder in adults: Treatment of mania and hypomania&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=rapid-cycling-bipolar-disorder-epidemiology-pathogenesis-clinical-features-and-diagnosis\" class=\"medical medical_review\">&quot;Rapid cycling bipolar disorder: Epidemiology, pathogenesis, clinical features, and diagnosis&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=bipolar-disorder-in-adults-assessment-and-diagnosis#H4503550\" class=\"medical medical_review\">&quot;Bipolar disorder in adults: Assessment and diagnosis&quot;, section on 'Diagnosis'</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=bipolar-disorder-in-adults-choosing-pharmacotherapy-for-acute-mania-and-hypomania\" class=\"medical medical_review\">&quot;Bipolar disorder in adults: Choosing pharmacotherapy for acute mania and hypomania&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=bipolar-disorder-in-adults-pharmacotherapy-for-acute-depression\" class=\"medical medical_review\">&quot;Bipolar disorder in adults: Pharmacotherapy for acute depression&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=bipolar-disorder-in-adults-choosing-maintenance-treatment\" class=\"medical medical_review\">&quot;Bipolar disorder in adults: Choosing maintenance treatment&quot;</a>.)</p><p/><p class=\"headingAnchor\" id=\"H92693295\"><span class=\"h1\">DEFINITION OF RAPID CYCLING BIPOLAR DISORDER</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Bipolar disorder is characterized by episodes of mania (<a href=\"image.htm?imageKey=PSYCH%2F91106\" class=\"graphic graphic_table graphicRef91106 \">table 1</a>), hypomania (<a href=\"image.htm?imageKey=PSYCH%2F91107\" class=\"graphic graphic_table graphicRef91107 \">table 2</a>), and major depression (<a href=\"image.htm?imageKey=PSYCH%2F91398\" class=\"graphic graphic_table graphicRef91398 \">table 3</a>) [<a href=\"https://www.uptodate.com/contents/rapid-cycling-bipolar-disorder-in-adults-treatment-of-major-depression/abstract/2\" class=\"abstract_t\">2</a>]. The subtypes of bipolar disorder include bipolar I and bipolar II. Patients with bipolar I disorder experience manic, and nearly always experience major depressive and hypomanic episodes. Bipolar II disorder is marked by at least one hypomanic episode, at least one major depressive episode, and the absence of manic. Additional information about the clinical features and diagnosis of bipolar disorder is discussed separately. (See <a href=\"topic.htm?path=bipolar-disorder-in-adults-clinical-features\" class=\"medical medical_review\">&quot;Bipolar disorder in adults: Clinical features&quot;</a> and <a href=\"topic.htm?path=bipolar-disorder-in-adults-assessment-and-diagnosis#H4503550\" class=\"medical medical_review\">&quot;Bipolar disorder in adults: Assessment and diagnosis&quot;, section on 'Diagnosis'</a>.)</p><p>Rapid cycling specifies a particular course of illness that can occur in bipolar I disorder or bipolar II disorder, rather than a subtype of bipolar disorder [<a href=\"https://www.uptodate.com/contents/rapid-cycling-bipolar-disorder-in-adults-treatment-of-major-depression/abstract/2\" class=\"abstract_t\">2</a>]. The diagnostic criteria for rapid cycling are as follows:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>At least four mood episodes in a 12-month period. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The episodes meet both the symptom and duration criteria for a manic, hypomanic, or major depressive episode; the episodes that occur as part of a rapid cycling pattern are no different from episodes that occur as part of a non-rapid cycling pattern.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The episodes are demarcated by a period of partial or full remission for at least two months, or by a switch to an episode of opposite polarity. Manic and hypomanic episodes are counted as being on the same pole; thus, a switch in polarity involves one of these episodes and an episode of major depression. </p><p/><p>Additional information about the clinical features and diagnosis of rapid cycling are discussed separately. (See <a href=\"topic.htm?path=rapid-cycling-bipolar-disorder-epidemiology-pathogenesis-clinical-features-and-diagnosis\" class=\"medical medical_review\">&quot;Rapid cycling bipolar disorder: Epidemiology, pathogenesis, clinical features, and diagnosis&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H92692334\"><span class=\"h1\">GENERAL PRINCIPLES</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Remission of a particular rapid cycling mood episode often occurs as a result of the course of illness, rather than treatment. Thus, the primary goal of treatment is to prevent further episodes.</p><p>Response to pharmacotherapy appears to be poorer in rapid cycling bipolar disorder than non-rapid cycling bipolar disorder [<a href=\"https://www.uptodate.com/contents/rapid-cycling-bipolar-disorder-in-adults-treatment-of-major-depression/abstract/5-9\" class=\"abstract_t\">5-9</a>]. A meta-analysis of nine studies (primarily observational, 1424 bipolar patients) examined improvement of mood episodes and rates of recurrence in rapid cycling and non-rapid cycling patients, and found that an inferior response to medications was more probable in rapid cycling patients (risk ratio 1.4, 95% CI 1.3-1.6) [<a href=\"https://www.uptodate.com/contents/rapid-cycling-bipolar-disorder-in-adults-treatment-of-major-depression/abstract/4\" class=\"abstract_t\">4</a>]. Clinicians may find that it is not feasible for rapid cycling patients to fully remit from a mood episode or avoid recurrences [<a href=\"https://www.uptodate.com/contents/rapid-cycling-bipolar-disorder-in-adults-treatment-of-major-depression/abstract/10\" class=\"abstract_t\">10</a>], and that a more realistic goal is to improve functioning and reduce the frequency, intensity, and duration of mood episodes [<a href=\"https://www.uptodate.com/contents/rapid-cycling-bipolar-disorder-in-adults-treatment-of-major-depression/abstract/4\" class=\"abstract_t\">4</a>]. The difficulties posed by rapid cycling usually necessitate referral to a psychiatrist.</p><p>Additional information about the general principles of treating rapid cycling bipolar disorder, including the frequency of monitoring patients and the duration of a treatment trial, are discussed separately. (See <a href=\"topic.htm?path=rapid-cycling-bipolar-disorder-in-adults-treatment-of-mania-and-hypomania#H86794887\" class=\"medical medical_review\">&quot;Rapid cycling bipolar disorder in adults: Treatment of mania and hypomania&quot;, section on 'General principles'</a>.)</p><p class=\"headingAnchor\" id=\"H928771508\"><span class=\"h2\">Use of antidepressants</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>There is a broad consensus that antidepressants should generally not be used in patients with rapid cycling [<a href=\"https://www.uptodate.com/contents/rapid-cycling-bipolar-disorder-in-adults-treatment-of-major-depression/abstract/11\" class=\"abstract_t\">11</a>]. Evidence supporting this approach includes a study of patients who were successfully treated for major depression with an antimanic drug (eg, <a href=\"topic.htm?path=lithium-drug-information\" class=\"drug drug_general\">lithium</a>) plus an antidepressant, and then randomly assigned to continue the antidepressant (n = 30) or discontinue the antidepressant (n = 37) [<a href=\"https://www.uptodate.com/contents/rapid-cycling-bipolar-disorder-in-adults-treatment-of-major-depression/abstract/12\" class=\"abstract_t\">12</a>]. In the group that continued antidepressants, more depressive episodes occurred in rapid cycling patients than nonrapid cycling patients. By contrast, in the group that discontinued antidepressants, the rate of subsequent depressive episodes was comparable [<a href=\"https://www.uptodate.com/contents/rapid-cycling-bipolar-disorder-in-adults-treatment-of-major-depression/abstract/12\" class=\"abstract_t\">12</a>]. &#160; </p><p class=\"headingAnchor\" id=\"H92694034\"><span class=\"h1\">TREATMENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Rapid cycling bipolar patients with major depression are typically treated with pharmacotherapy. However, refractory patients may benefit from electroconvulsive therapy (ECT).</p><p class=\"headingAnchor\" id=\"H92692341\"><span class=\"h2\">First line medication</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>We suggest <a href=\"topic.htm?path=quetiapine-drug-information\" class=\"drug drug_general\">quetiapine</a> as first line treatment for rapid cycling bipolar major depression based upon its efficacy and tolerability in randomized trials [<a href=\"https://www.uptodate.com/contents/rapid-cycling-bipolar-disorder-in-adults-treatment-of-major-depression/abstract/13-15\" class=\"abstract_t\">13-15</a>]. In addition, other randomized trials have demonstrated that quetiapine is efficacious for the general treatment of bipolar major depression [<a href=\"https://www.uptodate.com/contents/rapid-cycling-bipolar-disorder-in-adults-treatment-of-major-depression/abstract/16-20\" class=\"abstract_t\">16-20</a>].</p><p><a href=\"topic.htm?path=quetiapine-drug-information\" class=\"drug drug_general\">Quetiapine</a> is usually started at 50 mg at bedtime and titrated up by increments of 50 to 200 mg to achieve a target dose of 300 mg per day within four to seven days, provided that side effects do not intervene [<a href=\"https://www.uptodate.com/contents/rapid-cycling-bipolar-disorder-in-adults-treatment-of-major-depression/abstract/18\" class=\"abstract_t\">18</a>]. (Doses of 600 mg per day have been studied for bipolar major depression, but provide no advantage over a dose of 300 mg per day.) The side effects and pharmacology of quetiapine are discussed separately. </p><p>Evidence for the efficacy of <a href=\"topic.htm?path=quetiapine-drug-information\" class=\"drug drug_general\">quetiapine</a> for rapid cycling bipolar patients with major depression includes the following studies:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>An eight-week randomized trial compared <a href=\"topic.htm?path=quetiapine-drug-information\" class=\"drug drug_general\">quetiapine</a> (300 or 600 mg per day) with placebo for treating bipolar major depression [<a href=\"https://www.uptodate.com/contents/rapid-cycling-bipolar-disorder-in-adults-treatment-of-major-depression/abstract/18\" class=\"abstract_t\">18</a>]. In the subgroup with rapid cycling (n = 108), response (improvement from baseline on the depression rating scale &ge; 50 percent) occurred in significantly more patients who received quetiapine than placebo (66 versus 29 percent) [<a href=\"https://www.uptodate.com/contents/rapid-cycling-bipolar-disorder-in-adults-treatment-of-major-depression/abstract/8,13\" class=\"abstract_t\">8,13</a>]. This was consistent with the finding that each dose of quetiapine was superior to placebo in the total sample [<a href=\"https://www.uptodate.com/contents/rapid-cycling-bipolar-disorder-in-adults-treatment-of-major-depression/abstract/18\" class=\"abstract_t\">18</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>An eight-week randomized trial compared <a href=\"topic.htm?path=quetiapine-drug-information\" class=\"drug drug_general\">quetiapine</a> extended release (300 mg per day) with placebo for treating bipolar major depression [<a href=\"https://www.uptodate.com/contents/rapid-cycling-bipolar-disorder-in-adults-treatment-of-major-depression/abstract/14\" class=\"abstract_t\">14</a>]. In the subgroup with rapid cycling (n = 74), improvement was greater with quetiapine than placebo. This was consistent with the finding that quetiapine was superior in patients without rapid cycling (n = 196). &#160; </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A one-year, open-label, randomized study compared <a href=\"topic.htm?path=quetiapine-drug-information\" class=\"drug drug_general\">quetiapine</a> (mean dose 465 mg per day) with <a href=\"topic.htm?path=valproate-drug-information\" class=\"drug drug_general\">valproate</a> (mean dose 1340 mg per day) in 38 rapid cycling patients who were euthymic or primarily suffering from depressive symptoms at baseline [<a href=\"https://www.uptodate.com/contents/rapid-cycling-bipolar-disorder-in-adults-treatment-of-major-depression/abstract/21\" class=\"abstract_t\">21</a>]. Fewer days with moderate to severe depressive symptoms occurred in patients who received quetiapine than in patients who received valproate (12 versus 28 percent of days). </p><p/><p class=\"headingAnchor\" id=\"H92692348\"><span class=\"h2\">Resistant patients</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Many rapid cycling bipolar patients with major depression do not respond to <a href=\"topic.htm?path=quetiapine-drug-information\" class=\"drug drug_general\">quetiapine</a> [<a href=\"https://www.uptodate.com/contents/rapid-cycling-bipolar-disorder-in-adults-treatment-of-major-depression/abstract/8,13\" class=\"abstract_t\">8,13</a>]. For these resistant patients, we suggest sequential treatment with <a href=\"topic.htm?path=lamotrigine-drug-information\" class=\"drug drug_general\">lamotrigine</a>, <a href=\"topic.htm?path=lithium-drug-information\" class=\"drug drug_general\">lithium</a>, and the combination of <a href=\"topic.htm?path=olanzapine-drug-information\" class=\"drug drug_general\">olanzapine</a> and <a href=\"topic.htm?path=fluoxetine-drug-information\" class=\"drug drug_general\">fluoxetine</a>. To switch drugs, quetiapine is tapered and discontinued over one to two weeks at the same time that another medication is started and titrated up. We generally taper quetiapine by 50 to 200 mg per day, every one to two days. </p><p>The following drugs are listed in order of preference, based upon how often each drug has been studied and how well it worked. For resistant rapid cycling bipolar patients with major depression who do not respond to one second-line drug, or do not tolerate the drug, we suggest tapering and discontinuing the failed medication over one to two weeks at the same time that another second-line medication is started and titrated up. The failed medication is generally tapered by the same amount for each dose decrease. As an example, <a href=\"topic.htm?path=lamotrigine-drug-information\" class=\"drug drug_general\">lamotrigine</a> 200 mg per day is decreased by 50 mg per day, every two to three days.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=lamotrigine-drug-information\" class=\"drug drug_general\">Lamotrigine</a> &ndash; The initial dose of lamotrigine is 25 mg per day for weeks one and two. For weeks three and four, the dose is increased to 50 mg per day, taken in two divided doses (an extended release formulation is available for once a day dosing). The dose can then be titrated up by 25 to 50 mg per day, one week at a time for each increase. This slow titration reduces the risk of life-threatening skin rash, such as Stevens-Johnson syndrome. The target dose ranges from 50 to 300 mg per day [<a href=\"https://www.uptodate.com/contents/rapid-cycling-bipolar-disorder-in-adults-treatment-of-major-depression/abstract/22\" class=\"abstract_t\">22</a>]. The side effects and pharmacology of lamotrigine are discussed separately. (See <a href=\"topic.htm?path=antiseizure-drugs-mechanism-of-action-pharmacology-and-adverse-effects#H2007327377\" class=\"medical medical_review\">&quot;Antiseizure drugs: Mechanism of action, pharmacology, and adverse effects&quot;, section on 'Lamotrigine'</a>.)</p><p/><p class=\"bulletIndent1\">Evidence for the efficacy of <a href=\"topic.htm?path=lamotrigine-drug-information\" class=\"drug drug_general\">lamotrigine</a> in treating rapid cycling bipolar patients with major depression includes the following studies:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>A 26-week randomized trial compared <a href=\"topic.htm?path=lamotrigine-drug-information\" class=\"drug drug_general\">lamotrigine</a> (mean dose 288 mg per day) with placebo in 177 rapid cycling bipolar patients who were clinically stable for two weeks [<a href=\"https://www.uptodate.com/contents/rapid-cycling-bipolar-disorder-in-adults-treatment-of-major-depression/abstract/23\" class=\"abstract_t\">23</a>]. Relapse occurred in significantly fewer patients who received lamotrigine than placebo (59 versus 74 percent). In addition, discontinuation of treatment due to adverse side effects was identical for lamotrigine and placebo (two percent of each group). &#160;</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>A randomized, crossover trial compared <a href=\"topic.htm?path=lamotrigine-drug-information\" class=\"drug drug_general\">lamotrigine</a> (mean daily dose 274 mg per day) with placebo in 31 patients with treatment-resistant mood disorders (74 percent had rapid cycling bipolar disorder) [<a href=\"https://www.uptodate.com/contents/rapid-cycling-bipolar-disorder-in-adults-treatment-of-major-depression/abstract/24\" class=\"abstract_t\">24</a>]. In the total sample, response occurred in significantly more patients who received lamotrigine than placebo (52 versus 23 percent).</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>A 16-week, open-label, randomized trial (outcome assessed by blinded raters) compared <a href=\"topic.htm?path=lamotrigine-drug-information\" class=\"drug drug_general\">lamotrigine</a> (median dose 250 mg per day) with <a href=\"topic.htm?path=lithium-drug-information\" class=\"drug drug_general\">lithium</a> (median serum concentration 0.8 <span class=\"nowrap\">mmol/L)</span> in patients with bipolar major depression [<a href=\"https://www.uptodate.com/contents/rapid-cycling-bipolar-disorder-in-adults-treatment-of-major-depression/abstract/25\" class=\"abstract_t\">25</a>]. In the subgroup with rapid cycling (n = 68), significant improvement from baseline occurred with each drug, with no significant difference between the two medications; this was consistent with the finding that improvement with each drug was comparable in the total sample. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=lithium-drug-information\" class=\"drug drug_general\">Lithium</a> &ndash; The dose, side effects, and pharmacology of lithium, as well as the use of serum levels, are discussed separately. (See <a href=\"topic.htm?path=bipolar-disorder-in-adults-and-lithium-pharmacology-administration-and-side-effects\" class=\"medical medical_review\">&quot;Bipolar disorder in adults and lithium: Pharmacology, administration, and side effects&quot;</a>.)</p><p/><p class=\"bulletIndent1\">Evidence for the benefit of <a href=\"topic.htm?path=lithium-drug-information\" class=\"drug drug_general\">lithium</a> in treating depressed, rapid cycling patients includes the following studies:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>As discussed above, a study found that improvement of rapid cycling bipolar major depression was comparable for <a href=\"topic.htm?path=lithium-drug-information\" class=\"drug drug_general\">lithium</a> and <a href=\"topic.htm?path=lamotrigine-drug-information\" class=\"drug drug_general\">lamotrigine</a> [<a href=\"https://www.uptodate.com/contents/rapid-cycling-bipolar-disorder-in-adults-treatment-of-major-depression/abstract/25\" class=\"abstract_t\">25</a>]. </p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>A pooled analysis of three observational studies found that in 172 rapid cycling bipolar patients who were treated with <a href=\"topic.htm?path=lithium-drug-information\" class=\"drug drug_general\">lithium</a>, recurrent mood episodes did not occur in 34 percent [<a href=\"https://www.uptodate.com/contents/rapid-cycling-bipolar-disorder-in-adults-treatment-of-major-depression/abstract/26\" class=\"abstract_t\">26</a>]. In a separate pooled analysis of three observational studies with 90 rapid cycling patients who received lithium, the frequency, intensity, and duration of mood episodes decreased by 50 percent or more in 59 percent of patients. &#160;</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>A 12-week randomized trial compared <a href=\"topic.htm?path=lithium-drug-information\" class=\"drug drug_general\">lithium</a> with <a href=\"topic.htm?path=venlafaxine-drug-information\" class=\"drug drug_general\">venlafaxine</a> for treatment of bipolar depression, and the group of patients assigned to lithium included patients who were rapid cyclers (n = 28) and patients who were nonrapid cyclers (n = 36) [<a href=\"https://www.uptodate.com/contents/rapid-cycling-bipolar-disorder-in-adults-treatment-of-major-depression/abstract/27\" class=\"abstract_t\">27</a>]. Response (reduction of baseline symptoms &ge;50 percent) to lithium for rapid cyclers and nonrapid cyclers was comparable (39 and 31 percent of patients). </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=olanzapine-drug-information\" class=\"drug drug_general\">Olanzapine</a><strong> plus </strong><a href=\"topic.htm?path=fluoxetine-drug-information\" class=\"drug drug_general\">fluoxetine</a> &ndash; For patients who do not respond to sequential trials of <a href=\"topic.htm?path=quetiapine-drug-information\" class=\"drug drug_general\">quetiapine</a>, <a href=\"topic.htm?path=lamotrigine-drug-information\" class=\"drug drug_general\">lamotrigine</a>, and <a href=\"topic.htm?path=lithium-drug-information\" class=\"drug drug_general\">lithium</a>, we suggest olanzapine plus fluoxetine [<a href=\"https://www.uptodate.com/contents/rapid-cycling-bipolar-disorder-in-adults-treatment-of-major-depression/abstract/8,28\" class=\"abstract_t\">8,28</a>]. However, it is reasonable to use a different second-generation antipsychotic such as <a href=\"topic.htm?path=lurasidone-drug-information\" class=\"drug drug_general\">lurasidone</a> or quetiapine, <span class=\"nowrap\">and/or</span> to use a different selective serotonin reuptake inhibitor such as <a href=\"topic.htm?path=citalopram-drug-information\" class=\"drug drug_general\">citalopram</a>, <a href=\"topic.htm?path=escitalopram-drug-information\" class=\"drug drug_general\">escitalopram</a>, or <a href=\"topic.htm?path=sertraline-drug-information\" class=\"drug drug_general\">sertraline</a>. </p><p/><p class=\"bulletIndent1\">The initial dose of <a href=\"topic.htm?path=olanzapine-drug-information\" class=\"drug drug_general\">olanzapine</a> is generally 5 mg per day taken once daily, and the usual target dose range is 5 to 20 mg per day. Olanzapine is increased by 5 mg per day, every one to seven days, depending upon the intensity of specific symptoms, intervening side effects, and response to treatment. As an example, persistent insomnia should prompt a dose increase. The side effects and pharmacology of olanzapine are discussed separately. (See <a href=\"topic.htm?path=second-generation-antipsychotic-medications-pharmacology-administration-and-side-effects\" class=\"medical medical_review\">&quot;Second-generation antipsychotic medications: Pharmacology, administration, and side effects&quot;</a>.)</p><p/><p class=\"bulletIndent1\">The initial dose of <a href=\"topic.htm?path=fluoxetine-drug-information\" class=\"drug drug_general\">fluoxetine</a> is usually 20 mg per day taken once daily, and the target dose range is generally 20 to 60 mg per day. For patients who do not respond to 20 mg per day within two to four weeks, the dose is increased by 10 to 20 mg per day, depending on how well the medication is tolerated. Patients who remain unresponsive to treatment should receive additional increases of 10 to 20 mg per day every two to four weeks as tolerated, to an effective dose within the target dose range. We generally taper and discontinue fluoxetine over one to two weeks soon after the depressive syndrome has resolved (eg, within two to three months). Longer treatment may be associated with poorer outcomes [<a href=\"https://www.uptodate.com/contents/rapid-cycling-bipolar-disorder-in-adults-treatment-of-major-depression/abstract/12\" class=\"abstract_t\">12</a>]. Fluoxetine is decreased by 10 mg per day, every one to two days. The side effects and pharmacology of fluoxetine are discussed separately. (See <a href=\"topic.htm?path=selective-serotonin-reuptake-inhibitors-pharmacology-administration-and-side-effects\" class=\"medical medical_review\">&quot;Selective serotonin reuptake inhibitors: Pharmacology, administration, and side effects&quot;</a>.)</p><p/><p class=\"bulletIndent1\">Evidence for the efficacy of <a href=\"topic.htm?path=olanzapine-drug-information\" class=\"drug drug_general\">olanzapine</a> plus <a href=\"topic.htm?path=fluoxetine-drug-information\" class=\"drug drug_general\">fluoxetine</a> includes an eight-week randomized trial that compared olanzapine (mean dose 7 mg per day) plus fluoxetine (mean dose 40 mg per day) with placebo in patients with bipolar major depression [<a href=\"https://www.uptodate.com/contents/rapid-cycling-bipolar-disorder-in-adults-treatment-of-major-depression/abstract/28\" class=\"abstract_t\">28</a>]. In the subgroup with rapid cycling (n = 164), response (improvement from baseline on the depression rating scale &ge;50 percent) occurred in significantly more patients who received the combination than placebo (78 versus 39 percent) [<a href=\"https://www.uptodate.com/contents/rapid-cycling-bipolar-disorder-in-adults-treatment-of-major-depression/abstract/8,28\" class=\"abstract_t\">8,28</a>]. This was consistent with results in the total sample that found the combination was superior to placebo. In addition, discontinuation of treatment due to adverse side effects in the rapid cycling subgroup was comparable for patients who received the combination or placebo (5 and 3 percent), as was switching from major depression to mania or hypomania (10 versus 4 percent of patients) [<a href=\"https://www.uptodate.com/contents/rapid-cycling-bipolar-disorder-in-adults-treatment-of-major-depression/abstract/8\" class=\"abstract_t\">8</a>].</p><p/><p class=\"bulletIndent1\">Some authorities avoid antidepressants in rapid cycling bipolar patients with major depression [<a href=\"https://www.uptodate.com/contents/rapid-cycling-bipolar-disorder-in-adults-treatment-of-major-depression/abstract/29,30\" class=\"abstract_t\">29,30</a>], because observational studies suggest that antidepressants may exacerbate rapid cycling [<a href=\"https://www.uptodate.com/contents/rapid-cycling-bipolar-disorder-in-adults-treatment-of-major-depression/abstract/10\" class=\"abstract_t\">10</a>]. However, other observational studies [<a href=\"https://www.uptodate.com/contents/rapid-cycling-bipolar-disorder-in-adults-treatment-of-major-depression/abstract/26,31,32\" class=\"abstract_t\">26,31,32</a>] and randomized trials [<a href=\"https://www.uptodate.com/contents/rapid-cycling-bipolar-disorder-in-adults-treatment-of-major-depression/abstract/27\" class=\"abstract_t\">27</a>] have failed to find this association. The possible role of antidepressants in the pathogenesis of rapid cycling is discussed separately. (See <a href=\"topic.htm?path=rapid-cycling-bipolar-disorder-epidemiology-pathogenesis-clinical-features-and-diagnosis#H190200740\" class=\"medical medical_review\">&quot;Rapid cycling bipolar disorder: Epidemiology, pathogenesis, clinical features, and diagnosis&quot;, section on 'Antidepressants'</a>.)</p><p/><p class=\"headingAnchor\" id=\"H92692355\"><span class=\"h2\">Refractory patients</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Based upon several studies, rapid cycling bipolar patients with major depression frequently do not respond to pharmacotherapy [<a href=\"https://www.uptodate.com/contents/rapid-cycling-bipolar-disorder-in-adults-treatment-of-major-depression/abstract/9,23,25,33-35\" class=\"abstract_t\">9,23,25,33-35</a>]. For refractory patients whose depression does not respond to trials of <a href=\"topic.htm?path=quetiapine-drug-information\" class=\"drug drug_general\">quetiapine</a>, <a href=\"topic.htm?path=lamotrigine-drug-information\" class=\"drug drug_general\">lamotrigine</a>, <a href=\"topic.htm?path=lithium-drug-information\" class=\"drug drug_general\">lithium</a>, and the combination of <a href=\"topic.htm?path=olanzapine-drug-information\" class=\"drug drug_general\">olanzapine</a> and <a href=\"topic.htm?path=fluoxetine-drug-information\" class=\"drug drug_general\">fluoxetine</a>, we suggest electroconvulsive therapy (ECT). &#160;</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Electroconvulsive therapy (ECT)</strong> &ndash; ECT is generally safe and there are no absolute contraindications, even in patients whose general medical status is compromised [<a href=\"https://www.uptodate.com/contents/rapid-cycling-bipolar-disorder-in-adults-treatment-of-major-depression/abstract/36\" class=\"abstract_t\">36</a>]. However, safety concerns regarding ECT necessitate preprocedure medical consultation. Adverse effects include cardiopulmonary events, aspiration pneumonia, fractures, dental and tongue injuries, headache, nausea, and cognitive impairment. Medical consultation prior to ECT is discussed separately. (See <a href=\"topic.htm?path=medical-consultation-for-electroconvulsive-therapy\" class=\"medical medical_review\">&quot;Medical consultation for electroconvulsive therapy&quot;</a>.)</p><p/><p class=\"bulletIndent1\">Electrode placement and other aspects of ECT technique for treating rapid cycling bipolar patients with major depression have not been standardized. Thus, ECT is typically administered with the same technique used for other indications and is generally given three times per week on alternating days. Most patients regardless of indication remit with 6 to 12 treatments, but some patients may require 20 or more. Additional information about ECT is discussed separately. (See <a href=\"topic.htm?path=overview-of-electroconvulsive-therapy-ect-for-adults\" class=\"medical medical_review\">&quot;Overview of electroconvulsive therapy (ECT) for adults&quot;</a> and <a href=\"topic.htm?path=technique-for-performing-electroconvulsive-therapy-ect-in-adults\" class=\"medical medical_review\">&quot;Technique for performing electroconvulsive therapy (ECT) in adults&quot;</a>.)</p><p/><p class=\"bulletIndent1\">Evidence for the efficacy of ECT in treating rapid cycling bipolar patients with major depression includes studies that have found ECT is beneficial for the general population of patients with bipolar depression, who were not selected for rapid cycling. (See <a href=\"topic.htm?path=bipolar-disorder-in-adults-indications-for-and-efficacy-of-electroconvulsive-therapy-ect#H518772741\" class=\"medical medical_review\">&quot;Bipolar disorder in adults: Indications for and efficacy of electroconvulsive therapy (ECT)&quot;, section on 'Bipolar major depression'</a>.)</p><p/><p class=\"bulletIndent1\">Other evidence includes the following studies [<a href=\"https://www.uptodate.com/contents/rapid-cycling-bipolar-disorder-in-adults-treatment-of-major-depression/abstract/37-40\" class=\"abstract_t\">37-40</a>]:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>A prospective observational study followed 43 patients with rapid cycling bipolar disorder who received ECT; the mood episode resolved and there were no recurrences for at least one year in 26 percent, and temporary improvement occurred in the remaining patients [<a href=\"https://www.uptodate.com/contents/rapid-cycling-bipolar-disorder-in-adults-treatment-of-major-depression/abstract/29\" class=\"abstract_t\">29</a>].</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>In a retrospective study, 14 rapid cycling bipolar patients with major depression received ECT (mean number of treatments 23, mean duration of treatment 21 months) [<a href=\"https://www.uptodate.com/contents/rapid-cycling-bipolar-disorder-in-adults-treatment-of-major-depression/abstract/40\" class=\"abstract_t\">40</a>]. Rapid cycling resolved in every patient and the mean number of mood episodes per year decreased from six to one. However, another retrospective study found that among 24 patients with rapid cycling bipolar disorder who were treated with ECT, none remitted [<a href=\"https://www.uptodate.com/contents/rapid-cycling-bipolar-disorder-in-adults-treatment-of-major-depression/abstract/41\" class=\"abstract_t\">41</a>]. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Second-generation antipsychotic</strong> &ndash; For rapid cycling bipolar patients with refractory major depression who decline or do not have access to ECT, a reasonable alternative is an adjunctive second generation antipsychotic. A prospective observational study of 10 patients who were treated with adjunctive <a href=\"topic.htm?path=risperidone-drug-information\" class=\"drug drug_general\">risperidone</a> (2 to 6 mg per day) for at least six months found that mean depression rating scale scores decreased significantly from baseline [<a href=\"https://www.uptodate.com/contents/rapid-cycling-bipolar-disorder-in-adults-treatment-of-major-depression/abstract/42\" class=\"abstract_t\">42</a>]. However, second-generation antipsychotic monotherapy does not appear to be useful. An eight-week randomized trial compared <a href=\"topic.htm?path=olanzapine-drug-information\" class=\"drug drug_general\">olanzapine</a> monotherapy with placebo in bipolar patients with major depression [<a href=\"https://www.uptodate.com/contents/rapid-cycling-bipolar-disorder-in-adults-treatment-of-major-depression/abstract/28\" class=\"abstract_t\">28</a>]; in the subgroup with rapid cycling (n = 261), response (improvement from baseline on the depression rating scale &ge;50 percent) was comparable for olanzapine and placebo [<a href=\"https://www.uptodate.com/contents/rapid-cycling-bipolar-disorder-in-adults-treatment-of-major-depression/abstract/8\" class=\"abstract_t\">8</a>]. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=levothyroxine-drug-information\" class=\"drug drug_general\">Levothyroxine</a><strong> (T4) </strong>&ndash; For rapid cycling bipolar patients with refractory major depression who decline or do not have access to ECT, and do not respond to treatment with a second generation antipsychotic, a reasonable alternative is adjunctive levothyroxine (T4) [<a href=\"https://www.uptodate.com/contents/rapid-cycling-bipolar-disorder-in-adults-treatment-of-major-depression/abstract/43\" class=\"abstract_t\">43</a>]. Use of T4 for rapid cycling patients is discussed separately. (See <a href=\"topic.htm?path=rapid-cycling-bipolar-disorder-in-adults-treatment-of-mania-and-hypomania#H86796271\" class=\"medical medical_review\">&quot;Rapid cycling bipolar disorder in adults: Treatment of mania and hypomania&quot;, section on 'Refractory patients'</a>.)</p><p/><p class=\"headingAnchor\" id=\"H92692362\"><span class=\"h1\">ADJUNCTIVE PSYCHOTHERAPY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Augmenting pharmacotherapy with psychotherapy may possibly be useful for rapid cycling bipolar patients with major depression. We suggest psychoeducation (which teaches patients about the clinical features, treatment, and prognosis of rapid cycling bipolar disorder), based upon the demonstrated efficacy of adjunctive psychoeducation in a meta-analysis of six randomized trials for the general treatment of bipolar disorder [<a href=\"https://www.uptodate.com/contents/rapid-cycling-bipolar-disorder-in-adults-treatment-of-major-depression/abstract/44\" class=\"abstract_t\">44</a>]. However, reasonable alternatives include cognitive behavioral therapy (CBT), family therapy, and interpersonal social rhythm therapy. Adjunctive psychotherapy for treating bipolar disorder is discussed separately. (See <a href=\"topic.htm?path=bipolar-disorder-in-adults-choosing-maintenance-treatment#H20\" class=\"medical medical_review\">&quot;Bipolar disorder in adults: Choosing maintenance treatment&quot;, section on 'Choosing adjunctive psychotherapy'</a>.)</p><p>In a prospective observational study, 10 depressed or euthymic bipolar patients with rapid cycling were treated with 20 sessions of CBT that included psychoeducation, cognitive restructuring of depressive and manic thoughts (eg, &ldquo;No one loves me&rdquo; or &ldquo;I can afford to buy everything&rdquo;), and skills for managing mood shifts and comorbid psychiatric disorders [<a href=\"https://www.uptodate.com/contents/rapid-cycling-bipolar-disorder-in-adults-treatment-of-major-depression/abstract/45\" class=\"abstract_t\">45</a>]. Symptomatic improvement occurred in the six patients who completed the study. </p><p class=\"headingAnchor\" id=\"H4223989894\"><span class=\"h1\">SOCIETY GUIDELINE LINKS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See <a href=\"topic.htm?path=society-guideline-links-bipolar-disorder\" class=\"medical medical_society_guidelines\">&quot;Society guideline links: Bipolar disorder&quot;</a>.)</p><p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\"><span class=\"h1\">INFORMATION FOR PATIENTS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.) </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Basics topics (See <a href=\"topic.htm?path=bipolar-disorder-the-basics\" class=\"medical medical_basics\">&quot;Patient education: Bipolar disorder (The Basics)&quot;</a> and <a href=\"topic.htm?path=reducing-the-costs-of-medicines-the-basics\" class=\"medical medical_basics\">&quot;Patient education: Reducing the costs of medicines (The Basics)&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Beyond the Basics topics (See <a href=\"topic.htm?path=bipolar-disorder-manic-depression-beyond-the-basics\" class=\"medical medical_patient\">&quot;Patient education: Bipolar disorder (manic depression) (Beyond the Basics)&quot;</a> and <a href=\"topic.htm?path=reducing-the-costs-of-medicines-beyond-the-basics\" class=\"medical medical_patient\">&quot;Patient education: Reducing the costs of medicines (Beyond the Basics)&quot;</a>.)</p><p/><p>These educational materials can be used as part of psychoeducational psychotherapy. (See <a href=\"topic.htm?path=bipolar-disorder-in-adults-psychoeducation-and-other-adjunctive-maintenance-psychotherapies#H88286585\" class=\"medical medical_review\">&quot;Bipolar disorder in adults: Psychoeducation and other adjunctive maintenance psychotherapies&quot;, section on 'Group psychoeducation'</a>.) &#160;</p><p>The National Institute of Mental Health also has educational material explaining the symptoms, course of illness, and treatment of bipolar disorder in a booklet entitled &quot;Bipolar Disorder,&quot; which is available online at the website <a href=\"http://www.nimh.nih.gov/health/publications/bipolar-disorder/complete-index.shtml&amp;token=0tDNz8pYA0vPJ1c3GKnfXm6rR6Wn90h+lTkD0hPN0wKneShY4jnL7w6OiFvM8867fxs8Z2AHsbk+IUmVcN+gJ/p5aJLVr9XFHdaq6pnb/FI=&amp;TOPIC_ID=16890\" target=\"_blank\" class=\"external\">http://www.nimh.nih.gov/health/publications/bipolar-disorder/complete-index.shtml</a> or through a toll-free number, 866-615-6464. The web site also provides references, summaries of study results in language intended for the lay public, and information about clinical trials currently recruiting patients.</p><p>More comprehensive information is provided in many books written for patients and family members, including The Bipolar Disorder Survival Guide: What You and Your Family Need to Know, written by David J. Miklowitz, PhD (published by The Guilford Press, 2002); An Unquiet Mind: A Memoir of Moods and Madness, written by Kay Jamison, PhD (published by Random House, 1995); and Treatment of Bipolar Illness: A Casebook for Clinicians and Patients, by RM Post, MD, and GS Leverich, LCSW (published by Norton Press, 2008).</p><p>The Depression and Bipolar Support Alliance (<a href=\"http://www.dbsalliance.org/&amp;token=t/E/KJ/vXKbS8rOg3smveJKJLyGM2L6gx6ge/jIm6bXzlDqL73YpGHmVJdDt26oj&amp;TOPIC_ID=16890\" target=\"_blank\" class=\"external\">http://www.dbsalliance.org</a> or 800-826-3632) is a national organization that educates members about bipolar disorder and how to cope with it. Other functions include increasing public awareness of the illness and advocating for more research and services. The organization is administered and maintained by patients and family members, and has local chapters.</p><p>The National Alliance on Mental Illness (<a href=\"http://www.nami.org/&amp;token=0kQT3eXJw+rNOP0+8f9imR49WjqDpL2zjXCU8tX5vdg=&amp;TOPIC_ID=16890\" target=\"_blank\" class=\"external\">http://www.nami.org</a> or 800-950-6264) is a similarly structured organization devoted to education, support, and advocacy for patients with any mental illness. Bipolar disorder is one of their priorities.</p><p class=\"headingAnchor\" id=\"H92693814\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Bipolar disorder is characterized by episodes of mania (<a href=\"image.htm?imageKey=PSYCH%2F91106\" class=\"graphic graphic_table graphicRef91106 \">table 1</a>), hypomania (<a href=\"image.htm?imageKey=PSYCH%2F91107\" class=\"graphic graphic_table graphicRef91107 \">table 2</a>), and major depression (<a href=\"image.htm?imageKey=PSYCH%2F91398\" class=\"graphic graphic_table graphicRef91398 \">table 3</a>). (See <a href=\"#H92693295\" class=\"local\">'Definition of rapid cycling bipolar disorder'</a> above and <a href=\"topic.htm?path=bipolar-disorder-in-adults-assessment-and-diagnosis#H4503550\" class=\"medical medical_review\">&quot;Bipolar disorder in adults: Assessment and diagnosis&quot;, section on 'Diagnosis'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Rapid cycling bipolar disorder is diagnosed in patients with four or more mood episodes during a 12-month period. The episodes that occur during rapid cycling are no different from episodes that occur as part of a non-rapid cycling pattern. Separate episodes are demarcated from each other either by a switch from one pole to the other (eg, major depression to mania), or by full or partial remission for at least two months. (See <a href=\"#H92693295\" class=\"local\">'Definition of rapid cycling bipolar disorder'</a> above and <a href=\"topic.htm?path=rapid-cycling-bipolar-disorder-epidemiology-pathogenesis-clinical-features-and-diagnosis#H16495348\" class=\"medical medical_review\">&quot;Rapid cycling bipolar disorder: Epidemiology, pathogenesis, clinical features, and diagnosis&quot;, section on 'Diagnosis'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Remission of a particular rapid cycling mood episode often occurs as a result of the course of illness, rather than treatment. Thus, the primary goal of treatment is to prevent further episodes. (See <a href=\"#H92692334\" class=\"local\">'General principles'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For rapid cycling bipolar patients with major depression, we suggest initial treatment with <a href=\"topic.htm?path=quetiapine-drug-information\" class=\"drug drug_general\">quetiapine</a> rather than other drugs (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>). (See <a href=\"#H92692341\" class=\"local\">'First line medication'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For resistant rapid cycling bipolar patients with major depression that does not respond to <a href=\"topic.htm?path=quetiapine-drug-information\" class=\"drug drug_general\">quetiapine</a>, we suggest sequential treatment with <a href=\"topic.htm?path=lamotrigine-drug-information\" class=\"drug drug_general\">lamotrigine</a>, <a href=\"topic.htm?path=lithium-drug-information\" class=\"drug drug_general\">lithium</a>, and the combination of <a href=\"topic.htm?path=olanzapine-drug-information\" class=\"drug drug_general\">olanzapine</a> and <a href=\"topic.htm?path=fluoxetine-drug-information\" class=\"drug drug_general\">fluoxetine</a>, rather than other medications (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>). (See <a href=\"#H92692348\" class=\"local\">'Resistant patients'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For refractory rapid cycling bipolar patients with major depression that does not respond to trials of <a href=\"topic.htm?path=quetiapine-drug-information\" class=\"drug drug_general\">quetiapine</a>, <a href=\"topic.htm?path=lamotrigine-drug-information\" class=\"drug drug_general\">lamotrigine</a>, <a href=\"topic.htm?path=lithium-drug-information\" class=\"drug drug_general\">lithium</a>, and the combination of <a href=\"topic.htm?path=olanzapine-drug-information\" class=\"drug drug_general\">olanzapine</a> and <a href=\"topic.htm?path=fluoxetine-drug-information\" class=\"drug drug_general\">fluoxetine</a>, we suggest electroconvulsive therapy (ECT) rather than additional pharmacotherapy trials (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>). (See <a href=\"#H92692355\" class=\"local\">'Refractory patients'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For depressed rapid cycling bipolar patients, we suggest augmenting pharmacotherapy with psychotherapy rather than using pharmacotherapy alone (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>). We generally use psychoeducation; however, cognitive behavioral therapy (CBT), family therapy, and interpersonal social rhythm therapy are reasonable alternatives. (See <a href=\"#H92692362\" class=\"local\">'Adjunctive psychotherapy'</a> above.)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li class=\"breakAll\">Goodwin FK, Jamison KR. Manic-Depressive Illness: Bipolar Disorders and Recurrent Depression, Second Edition, Oxford University Press, Oxford 2007.</li><li class=\"breakAll\">American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), American Psychiatric Association, Arlington 2013.</li><li><a href=\"https://www.uptodate.com/contents/rapid-cycling-bipolar-disorder-in-adults-treatment-of-major-depression/abstract/3\" class=\"nounderline abstract_t\">Dunner DL, Fieve RR. Clinical factors in lithium carbonate prophylaxis failure. Arch Gen Psychiatry 1974; 30:229.</a></li><li><a href=\"https://www.uptodate.com/contents/rapid-cycling-bipolar-disorder-in-adults-treatment-of-major-depression/abstract/4\" class=\"nounderline abstract_t\">Tondo L, Hennen J, Baldessarini RJ. Rapid-cycling bipolar disorder: effects of long-term treatments. Acta Psychiatr Scand 2003; 108:4.</a></li><li><a href=\"https://www.uptodate.com/contents/rapid-cycling-bipolar-disorder-in-adults-treatment-of-major-depression/abstract/5\" class=\"nounderline abstract_t\">Bauer M, Beaulieu S, Dunner DL, et al. Rapid cycling bipolar disorder--diagnostic concepts. Bipolar Disord 2008; 10:153.</a></li><li class=\"breakAll\">Kupka RW, Frye MA. Diagnosis and treatment of rapid cycling bipolar disorder. In: Yatham L, Kusumakar V (Ed.) Bipolar Disorder. A clinician&rsquo;s guide to biological treatments, 2nd Ed. New York, Brunner-Routledge, 2009.</li><li class=\"breakAll\">National Institute for Health and Clinical Excellence. Bipolar disorder: The management of bipolar disorder in adults, children and adolescents, in primary and secondary care. NICE Clinical Guideline 185, 2014. http://guidance.nice.org.uk/cg185 (Accessed on December 31, 2014).</li><li class=\"breakAll\">Ketter TA, Wang PW. Management of rapid-cycling bipolar disorders. In: Handbook of Diagnosis and Treatment of Bipolar Disorders, Ketter TA (Ed), American Psychiatric Publishing, Inc, Washington, DC 2010. p.331.</li><li><a href=\"https://www.uptodate.com/contents/rapid-cycling-bipolar-disorder-in-adults-treatment-of-major-depression/abstract/9\" class=\"nounderline abstract_t\">Schneck CD. Treatment of rapid-cycling bipolar disorder. J Clin Psychiatry 2006; 67 Suppl 11:22.</a></li><li><a href=\"https://www.uptodate.com/contents/rapid-cycling-bipolar-disorder-in-adults-treatment-of-major-depression/abstract/10\" class=\"nounderline abstract_t\">Schneck CD, Miklowitz DJ, Miyahara S, et al. The prospective course of rapid-cycling bipolar disorder: findings from the STEP-BD. Am J Psychiatry 2008; 165:370.</a></li><li><a href=\"https://www.uptodate.com/contents/rapid-cycling-bipolar-disorder-in-adults-treatment-of-major-depression/abstract/11\" class=\"nounderline abstract_t\">Pacchiarotti I, Bond DJ, Baldessarini RJ, et al. The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders. Am J Psychiatry 2013; 170:1249.</a></li><li><a href=\"https://www.uptodate.com/contents/rapid-cycling-bipolar-disorder-in-adults-treatment-of-major-depression/abstract/12\" class=\"nounderline abstract_t\">El-Mallakh RS, V&ouml;hringer PA, Ostacher MM, et al. Antidepressants worsen rapid-cycling course in bipolar depression: A STEP-BD randomized clinical trial. J Affect Disord 2015; 184:318.</a></li><li><a href=\"https://www.uptodate.com/contents/rapid-cycling-bipolar-disorder-in-adults-treatment-of-major-depression/abstract/13\" class=\"nounderline abstract_t\">Vieta E, Calabrese JR, Goikolea JM, et al. Quetiapine monotherapy in the treatment of patients with bipolar I or II depression and a rapid-cycling disease course: a randomized, double-blind, placebo-controlled study. Bipolar Disord 2007; 9:413.</a></li><li><a href=\"https://www.uptodate.com/contents/rapid-cycling-bipolar-disorder-in-adults-treatment-of-major-depression/abstract/14\" class=\"nounderline abstract_t\">Suppes T, Datto C, Minkwitz M, et al. Effectiveness of the extended release formulation of quetiapine as monotherapy for the treatment of acute bipolar depression. J Affect Disord 2010; 121:106.</a></li><li><a href=\"https://www.uptodate.com/contents/rapid-cycling-bipolar-disorder-in-adults-treatment-of-major-depression/abstract/15\" class=\"nounderline abstract_t\">Thase ME, Macfadden W, Weisler RH, et al. Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study). J Clin Psychopharmacol 2006; 26:600.</a></li><li><a href=\"https://www.uptodate.com/contents/rapid-cycling-bipolar-disorder-in-adults-treatment-of-major-depression/abstract/16\" class=\"nounderline abstract_t\">Young AH, McElroy SL, Bauer M, et al. A double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I). J Clin Psychiatry 2010; 71:150.</a></li><li><a href=\"https://www.uptodate.com/contents/rapid-cycling-bipolar-disorder-in-adults-treatment-of-major-depression/abstract/17\" class=\"nounderline abstract_t\">McElroy SL, Weisler RH, Chang W, et al. A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II). J Clin Psychiatry 2010; 71:163.</a></li><li><a href=\"https://www.uptodate.com/contents/rapid-cycling-bipolar-disorder-in-adults-treatment-of-major-depression/abstract/18\" class=\"nounderline abstract_t\">Calabrese JR, Keck PE Jr, Macfadden W, et al. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry 2005; 162:1351.</a></li><li><a href=\"https://www.uptodate.com/contents/rapid-cycling-bipolar-disorder-in-adults-treatment-of-major-depression/abstract/19\" class=\"nounderline abstract_t\">Swartz HA, Thase ME. Pharmacotherapy for the treatment of acute bipolar II depression: current evidence. J Clin Psychiatry 2011; 72:356.</a></li><li><a href=\"https://www.uptodate.com/contents/rapid-cycling-bipolar-disorder-in-adults-treatment-of-major-depression/abstract/20\" class=\"nounderline abstract_t\">Nivoli AM, Colom F, Murru A, et al. New treatment guidelines for acute bipolar depression: a systematic review. J Affect Disord 2011; 129:14.</a></li><li><a href=\"https://www.uptodate.com/contents/rapid-cycling-bipolar-disorder-in-adults-treatment-of-major-depression/abstract/21\" class=\"nounderline abstract_t\">Langosch JM, Drieling T, Biedermann NC, et al. Efficacy of quetiapine monotherapy in rapid-cycling bipolar disorder in comparison with sodium valproate. J Clin Psychopharmacol 2008; 28:555.</a></li><li><a href=\"https://www.uptodate.com/contents/rapid-cycling-bipolar-disorder-in-adults-treatment-of-major-depression/abstract/22\" class=\"nounderline abstract_t\">Tritt K, Nickel C, Lahmann C, et al. Lamotrigine treatment of aggression in female borderline-patients: a randomized, double-blind, placebo-controlled study. J Psychopharmacol 2005; 19:287.</a></li><li><a href=\"https://www.uptodate.com/contents/rapid-cycling-bipolar-disorder-in-adults-treatment-of-major-depression/abstract/23\" class=\"nounderline abstract_t\">Calabrese JR, Suppes T, Bowden CL, et al. A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. Lamictal 614 Study Group. J Clin Psychiatry 2000; 61:841.</a></li><li><a href=\"https://www.uptodate.com/contents/rapid-cycling-bipolar-disorder-in-adults-treatment-of-major-depression/abstract/24\" class=\"nounderline abstract_t\">Frye MA, Ketter TA, Kimbrell TA, et al. A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. J Clin Psychopharmacol 2000; 20:607.</a></li><li><a href=\"https://www.uptodate.com/contents/rapid-cycling-bipolar-disorder-in-adults-treatment-of-major-depression/abstract/25\" class=\"nounderline abstract_t\">Suppes T, Marangell LB, Bernstein IH, et al. A single blind comparison of lithium and lamotrigine for the treatment of bipolar II depression. J Affect Disord 2008; 111:334.</a></li><li><a href=\"https://www.uptodate.com/contents/rapid-cycling-bipolar-disorder-in-adults-treatment-of-major-depression/abstract/26\" class=\"nounderline abstract_t\">Kupka RW, Luckenbaugh DA, Post RM, et al. Rapid and non-rapid cycling bipolar disorder: a meta-analysis of clinical studies. J Clin Psychiatry 2003; 64:1483.</a></li><li><a href=\"https://www.uptodate.com/contents/rapid-cycling-bipolar-disorder-in-adults-treatment-of-major-depression/abstract/27\" class=\"nounderline abstract_t\">Lorenzo-Luaces L, Amsterdam JD, Soeller I, DeRubeis RJ. Rapid versus non-rapid cycling bipolar II depression: response to venlafaxine and lithium and hypomanic risk. Acta Psychiatr Scand 2016; 133:459.</a></li><li><a href=\"https://www.uptodate.com/contents/rapid-cycling-bipolar-disorder-in-adults-treatment-of-major-depression/abstract/28\" class=\"nounderline abstract_t\">Tohen M, Vieta E, Calabrese J, et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry 2003; 60:1079.</a></li><li><a href=\"https://www.uptodate.com/contents/rapid-cycling-bipolar-disorder-in-adults-treatment-of-major-depression/abstract/29\" class=\"nounderline abstract_t\">Koukopoulos A, Sani G, Koukopoulos AE, et al. Duration and stability of the rapid-cycling course: a long-term personal follow-up of 109 patients. J Affect Disord 2003; 73:75.</a></li><li><a href=\"https://www.uptodate.com/contents/rapid-cycling-bipolar-disorder-in-adults-treatment-of-major-depression/abstract/30\" class=\"nounderline abstract_t\">Ghaemi SN. Treatment of rapid-cycling bipolar disorder: are antidepressants mood destabilizers? Am J Psychiatry 2008; 165:300.</a></li><li><a href=\"https://www.uptodate.com/contents/rapid-cycling-bipolar-disorder-in-adults-treatment-of-major-depression/abstract/31\" class=\"nounderline abstract_t\">Coryell W. Rapid cycling bipolar disorder: clinical characteristics and treatment options. CNS Drugs 2005; 19:557.</a></li><li><a href=\"https://www.uptodate.com/contents/rapid-cycling-bipolar-disorder-in-adults-treatment-of-major-depression/abstract/32\" class=\"nounderline abstract_t\">Goodwin GM, Consensus Group of the British Association for Psychopharmacology. Evidence-based guidelines for treating bipolar disorder: revised second edition--recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2009; 23:346.</a></li><li><a href=\"https://www.uptodate.com/contents/rapid-cycling-bipolar-disorder-in-adults-treatment-of-major-depression/abstract/33\" class=\"nounderline abstract_t\">Calabrese JR, Shelton MD, Rapport DJ, et al. A 20-month, double-blind, maintenance trial of lithium versus divalproex in rapid-cycling bipolar disorder. Am J Psychiatry 2005; 162:2152.</a></li><li><a href=\"https://www.uptodate.com/contents/rapid-cycling-bipolar-disorder-in-adults-treatment-of-major-depression/abstract/34\" class=\"nounderline abstract_t\">Kemp DE, Gao K, Ganocy SJ, et al. A 6-month, double-blind, maintenance trial of lithium monotherapy versus the combination of lithium and divalproex for rapid-cycling bipolar disorder and Co-occurring substance abuse or dependence. J Clin Psychiatry 2009; 70:113.</a></li><li><a href=\"https://www.uptodate.com/contents/rapid-cycling-bipolar-disorder-in-adults-treatment-of-major-depression/abstract/35\" class=\"nounderline abstract_t\">Calabrese JR, Shelton MD, Bowden CL, et al. Bipolar rapid cycling: focus on depression as its hallmark. J Clin Psychiatry 2001; 62 Suppl 14:34.</a></li><li class=\"breakAll\">American Psychiatric Association Task Force on Electroconvulsive Therapy. The Practice of Electroconvulsive Therapy: Recommendations for Treatment, Training, and Privileging. American Psychiatric Association, Washington, DC 2001.</li><li><a href=\"https://www.uptodate.com/contents/rapid-cycling-bipolar-disorder-in-adults-treatment-of-major-depression/abstract/37\" class=\"nounderline abstract_t\">Vanelle JM, Loo H, Galinowski A, et al. Maintenance ECT in intractable manic-depressive disorders. Convuls Ther 1994; 10:195.</a></li><li><a href=\"https://www.uptodate.com/contents/rapid-cycling-bipolar-disorder-in-adults-treatment-of-major-depression/abstract/38\" class=\"nounderline abstract_t\">Kho KH. Treatment of rapid cycling bipolar disorder in the acute and maintenance phase with ECT. J ECT 2002; 18:159.</a></li><li><a href=\"https://www.uptodate.com/contents/rapid-cycling-bipolar-disorder-in-adults-treatment-of-major-depression/abstract/39\" class=\"nounderline abstract_t\">Berman E, Wolpert EA. Intractable manic-depressive psychosis with rapid cycling in an 18-year-old woman successfully treated with electroconvulsive therapy. J Nerv Ment Dis 1987; 175:236.</a></li><li><a href=\"https://www.uptodate.com/contents/rapid-cycling-bipolar-disorder-in-adults-treatment-of-major-depression/abstract/40\" class=\"nounderline abstract_t\">Minnai GP, Salis PG, Oppo R, et al. Effectiveness of maintenance electroconvulsive therapy in rapid-cycling bipolar disorder. J ECT 2011; 27:123.</a></li><li><a href=\"https://www.uptodate.com/contents/rapid-cycling-bipolar-disorder-in-adults-treatment-of-major-depression/abstract/41\" class=\"nounderline abstract_t\">Wehr TA, Sack DA, Rosenthal NE, Cowdry RW. Rapid cycling affective disorder: contributing factors and treatment responses in 51 patients. Am J Psychiatry 1988; 145:179.</a></li><li><a href=\"https://www.uptodate.com/contents/rapid-cycling-bipolar-disorder-in-adults-treatment-of-major-depression/abstract/42\" class=\"nounderline abstract_t\">Vieta E, Gasto C, Colom F, et al. Treatment of refractory rapid cycling bipolar disorder with risperidone. J Clin Psychopharmacol 1998; 18:172.</a></li><li><a href=\"https://www.uptodate.com/contents/rapid-cycling-bipolar-disorder-in-adults-treatment-of-major-depression/abstract/43\" class=\"nounderline abstract_t\">Bauer M, Adli M, Bschor T, et al.. Clinical applications of levothyroxine in refractory mood disorders. Clinical Approaches in Bipolar Disorders 2003; 2:49.</a></li><li><a href=\"https://www.uptodate.com/contents/rapid-cycling-bipolar-disorder-in-adults-treatment-of-major-depression/abstract/44\" class=\"nounderline abstract_t\">Morriss RK, Faizal MA, Jones AP, et al. Interventions for helping people recognise early signs of recurrence in bipolar disorder. Cochrane Database Syst Rev 2007; :CD004854.</a></li><li><a href=\"https://www.uptodate.com/contents/rapid-cycling-bipolar-disorder-in-adults-treatment-of-major-depression/abstract/45\" class=\"nounderline abstract_t\">Reilly-Harrington NA, Deckersbach T, Knauz R, et al. Cognitive behavioral therapy for rapid-cycling bipolar disorder: a pilot study. J Psychiatr Pract 2007; 13:291.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 16890 Version 14.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H92693814\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H92693288\" id=\"outline-link-H92693288\">INTRODUCTION</a></li><li><a href=\"#H92693295\" id=\"outline-link-H92693295\">DEFINITION OF RAPID CYCLING BIPOLAR DISORDER</a></li><li><a href=\"#H92692334\" id=\"outline-link-H92692334\">GENERAL PRINCIPLES</a><ul><li><a href=\"#H928771508\" id=\"outline-link-H928771508\">Use of antidepressants</a></li></ul></li><li><a href=\"#H92694034\" id=\"outline-link-H92694034\">TREATMENT</a><ul><li><a href=\"#H92692341\" id=\"outline-link-H92692341\">First line medication</a></li><li><a href=\"#H92692348\" id=\"outline-link-H92692348\">Resistant patients</a></li><li><a href=\"#H92692355\" id=\"outline-link-H92692355\">Refractory patients</a></li></ul></li><li><a href=\"#H92692362\" id=\"outline-link-H92692362\">ADJUNCTIVE PSYCHOTHERAPY</a></li><li><a href=\"#H4223989894\" id=\"outline-link-H4223989894\">SOCIETY GUIDELINE LINKS</a></li><li><a href=\"#PATIENT_INFORMATION\" id=\"outline-link-H13496395\">INFORMATION FOR PATIENTS</a></li><li><a href=\"#H92693814\" id=\"outline-link-H92693814\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"PSYCH/16890|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=PSYCH/91106\" class=\"graphic graphic_table\">- DSM-5 diagnostic criteria for manic episode</a></li><li><a href=\"image.htm?imageKey=PSYCH/91107\" class=\"graphic graphic_table\">- DSM-5 diagnostic criteria for hypomanic episode</a></li><li><a href=\"image.htm?imageKey=PSYCH/91398\" class=\"graphic graphic_table\">- DSM-5 diagnostic criteria for bipolar major depression</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=antiseizure-drugs-mechanism-of-action-pharmacology-and-adverse-effects\" class=\"medical medical_review\">Antiseizure drugs: Mechanism of action, pharmacology, and adverse effects</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=bipolar-disorder-in-adults-and-lithium-pharmacology-administration-and-side-effects\" class=\"medical medical_review\">Bipolar disorder in adults and lithium: Pharmacology, administration, and side effects</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=bipolar-disorder-in-adults-assessment-and-diagnosis\" class=\"medical medical_review\">Bipolar disorder in adults: Assessment and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=bipolar-disorder-in-adults-choosing-maintenance-treatment\" class=\"medical medical_review\">Bipolar disorder in adults: Choosing maintenance treatment</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=bipolar-disorder-in-adults-choosing-pharmacotherapy-for-acute-mania-and-hypomania\" class=\"medical medical_review\">Bipolar disorder in adults: Choosing pharmacotherapy for acute mania and hypomania</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=bipolar-disorder-in-adults-clinical-features\" class=\"medical medical_review\">Bipolar disorder in adults: Clinical features</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=bipolar-disorder-in-adults-indications-for-and-efficacy-of-electroconvulsive-therapy-ect\" class=\"medical medical_review\">Bipolar disorder in adults: Indications for and efficacy of electroconvulsive therapy (ECT)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=bipolar-disorder-in-adults-pharmacotherapy-for-acute-depression\" class=\"medical medical_review\">Bipolar disorder in adults: Pharmacotherapy for acute depression</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=bipolar-disorder-in-adults-psychoeducation-and-other-adjunctive-maintenance-psychotherapies\" class=\"medical medical_review\">Bipolar disorder in adults: Psychoeducation and other adjunctive maintenance psychotherapies</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=medical-consultation-for-electroconvulsive-therapy\" class=\"medical medical_review\">Medical consultation for electroconvulsive therapy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-electroconvulsive-therapy-ect-for-adults\" class=\"medical medical_review\">Overview of electroconvulsive therapy (ECT) for adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=bipolar-disorder-the-basics\" class=\"medical medical_basics\">Patient education: Bipolar disorder (The Basics)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=bipolar-disorder-manic-depression-beyond-the-basics\" class=\"medical medical_patient\">Patient education: Bipolar disorder (manic depression) (Beyond the Basics)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=reducing-the-costs-of-medicines-beyond-the-basics\" class=\"medical medical_patient\">Patient education: Reducing the costs of medicines (Beyond the Basics)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=reducing-the-costs-of-medicines-the-basics\" class=\"medical medical_basics\">Patient education: Reducing the costs of medicines (The Basics)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=rapid-cycling-bipolar-disorder-in-adults-treatment-of-mania-and-hypomania\" class=\"medical medical_review\">Rapid cycling bipolar disorder in adults: Treatment of mania and hypomania</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=rapid-cycling-bipolar-disorder-epidemiology-pathogenesis-clinical-features-and-diagnosis\" class=\"medical medical_review\">Rapid cycling bipolar disorder: Epidemiology, pathogenesis, clinical features, and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=second-generation-antipsychotic-medications-pharmacology-administration-and-side-effects\" class=\"medical medical_review\">Second-generation antipsychotic medications: Pharmacology, administration, and side effects</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=selective-serotonin-reuptake-inhibitors-pharmacology-administration-and-side-effects\" class=\"medical medical_review\">Selective serotonin reuptake inhibitors: Pharmacology, administration, and side effects</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=society-guideline-links-bipolar-disorder\" class=\"medical medical_society_guidelines\">Society guideline links: Bipolar disorder</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=technique-for-performing-electroconvulsive-therapy-ect-in-adults\" class=\"medical medical_review\">Technique for performing electroconvulsive therapy (ECT) in adults</a></li></ul></div></div>","javascript":null}